This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
tim.hodson Tue, 03/25/2025 - 16:19 March 25, 2025 Bayer plans to present data from 13 new analyses from across the KERENDIA (finerenone) comprehensive clinical trial program at the American College of Cardiology (ACC) 74 th Annual Scientific Session & Expo 2025 , in Chicago, IL, March 29-31, 2025. Additional ACC.25
Circulation, Volume 151, Issue 10 , Page 716-732, March 11, 2025. Albuminuriaincreased urine albumin excretionis associated with cardiovascular mortality among patients with diabetes, hypertension, chronic kidneydisease, or heart failure, as well as among adults with few cardiovascular risk factors.
tim.hodson Tue, 03/25/2025 - 16:19 March 25, 2025 Bayer plans to present data from 13 new analyses from across t he KERENDIA (finerenone) comprehensive clinical trial program at the American College of Cardiology (ACC) 74 th Annual Scientific Session & Expo 2025 , in Chicago, IL, March 29-31, 2025. Additional ACC.25
Stroke, Volume 56, Issue Suppl_1 , Page ADP47-ADP47, February 1, 2025. Introduction:Chronic kidneydisease (CKD) is a risk factor for intracerebral hemorrhage (ICH) and for worse outcomes following ICH.
Stroke, Volume 56, Issue Suppl_1 , Page A102-A102, February 1, 2025. Background and Purpose:Chronic kidneydisease (CKD) is associated with an increased risk of stroke and worse outcomes, yet it is often asymptomatic, with an estimated 90% of individuals unaware they have CKD until its later stages.
Additionally, 10% of the global population suffers from chronic kidneydisease , with diabetes and hypertension as significant risk factors. Disparities in care are also concerning, with diagnosed cardiometabolic diseases varying up to twofold among different racial and ethnic groups. .” In the U.S.,
Both reperfusion, as judged by the biomarker curve, and patency, as assessed by the angiogram, were correlated with the rapidity and depth of T wave inversion. link] == MY Comment , by K EN G RAUER, MD ( 1/14 /2025 ): == I found today's case highly insightful with regard to many aspects. 2018, July 30). American College of Cardiology.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content